MRI in colon carcinoma: diagnostic value in assessing pathologic regression with therapy

MRI in colon carcinoma: diagnostic value in assessing pathologic regression with therapy - MRI in colorectal cancer

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00031742

Enrollment

Registered

2023-04-21

Start date

2023-05-11

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C20 C18.7 C19

Interventions

Group 1: Due to the prospective design of the study, there are no additional risks for the patients. After inclusion of the patient in the study, imaging is routinely performed under therapy and follo

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: ? Diagnosis of colorectal carcinoma. ? Request for routine clinical MRI of the liver for staging. ? Treatment plan with future potential resection of the primary (to determine pTRG) and distant metastases, if applicable.

Exclusion criteria

Exclusion criteria: ? Contraindication to administration of buscopan to decrease intestinal motility. ? Non-diagnostic MRI examination of the colon.

Design outcomes

Primary

Measure	Time frame
To investigate the diagnostic accuracy of MR morphological tumor regression grade (mrTRG) compared to pathological tumor regression grade (pTRG).	—

Secondary

Measure	Time frame
To investigate the prognostic value of MRI-based findings with overall survival. These include MRI-defined extramural vascular invasion (EMVI), apparent diffusion coefficient (ADC) / IVIM score, and kurtosis score.	—

Countries

Germany

Contacts

Public ContactWolfgang Kunz

LMU Klinik und Poliklinik für Radiologie

wolfgang.kunz@med.uni-muenchen.de089 4400-73630

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026